![Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419369261-gr2.jpg)
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect
![The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer—A retrospective cohort study - Tong - 2018 - Cancer Medicine - Wiley Online Library The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer—A retrospective cohort study - Tong - 2018 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/17816739-d87c-4cae-a80c-b7669a08efac/cam41814-fig-0001-m.jpg)
The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer—A retrospective cohort study - Tong - 2018 - Cancer Medicine - Wiley Online Library
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on lon
![Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301120-fx1.jpg)
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect
![CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/33/1/253/F2.large.jpg)
CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research
![IJMS | Free Full-Text | A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer IJMS | Free Full-Text | A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer](https://pub.mdpi-res.com/ijms/ijms-23-12969/article_deploy/html/images/ijms-23-12969-g004.png?1666788919)
IJMS | Free Full-Text | A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer
![CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01483-x/MediaObjects/41416_2021_1483_Fig1_HTML.png)
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer
![Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419369261-gr3.jpg)
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy - ScienceDirect
![CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/33/1/253/F1.large.jpg)
CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer | Anticancer Research
![Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer | Scientific Reports Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-21048-y/MediaObjects/41598_2018_21048_Fig1_HTML.jpg)
Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer | Scientific Reports
![Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10147-019-01597-6/MediaObjects/10147_2019_1597_Fig5_HTML.png)
Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink
Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma | PLOS ONE
![Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram](https://www.researchgate.net/publication/236911183/figure/fig3/AS:667807037521931@1536229013931/Fluctuations-in-calcitonin-Calcitonin-CEA-and-RECIST-are-graphed-as-a-percent-of.png)
Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram
![Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram](https://www.researchgate.net/profile/David-Hong-8/publication/236911183/figure/fig3/AS:667807037521931@1536229013931/Fluctuations-in-calcitonin-Calcitonin-CEA-and-RECIST-are-graphed-as-a-percent-of_Q640.jpg)
Fluctuations in calcitonin. Calcitonin, CEA and RECIST are graphed as a... | Download Scientific Diagram
![Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10147-019-01597-6/MediaObjects/10147_2019_1597_Fig6_HTML.png)
Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA | SpringerLink
![Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin | Anticancer Research Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/38/3/1711/F1.large.jpg)
Case Report: CEA Elevation Can Be a Marker of Increased Inflammation During Treatment with Oxaliplatin | Anticancer Research
![The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-4987-0/MediaObjects/12885_2018_4987_Fig2_HTML.png)
The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text
![Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients](https://www.spandidos-publications.com/article_images/ol/14/6/ol-14-06-7549-g00.jpg)
Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients
![The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-4987-0/MediaObjects/12885_2018_4987_Fig1_HTML.png)